Everything on Pharmaceutical Economics

Novo Nordisk is facing a sales decline because price cuts in the GLP-1 market are outpacing volume growth, even with high demand.

Impact: This signals a shift in pharma economics from high-margin blockbuster models to volume-driven, lower-margin competition.

— from AI Disruption, GLP-1 Price Wars, and EV Safety · WSJ What’s News· Feb 04, 2026